NCT02721732 2026-01-29
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of California, San Francisco
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
AHS Cancer Control Alberta